在癌症病患者出现改善后, 库拉尼克斯股价上升. Curanex shares rose after a cancer cachexia patient showed improvements.

库拉尼克斯制药股价周一上, 一项患者病例研究显示Phyto-N的能量和实验室标记有所改善. 这是一种正在开发用于癌症缓解性反应的化合物. Shares of Curanex Pharmaceuticals rose Monday after a patient case study showed improvements in energy and lab markers for Phyto-N, a compound under development for cancer cachexia. 患者是一名胰腺瘤的剂量计师, 一个月内出现了显著变化. The patient, a dosimetrist with a pancreatic tumor, experienced notable changes within a month. 该公司强调了这种未满足的医疗需求的潜力,并通过临床前工作推动Phyto-N. The company emphasized the potential of this unmet medical need and is advancing Phyto-N through preclinical work.